Abstract：
Molecular breast imaging (MBI) is a nuclear medicine technique that has evolved considerably over the past two decades. Technical advances have allowed reductions in administered doses to the point that they are now acceptable for screening. The most common radiotracer used in MBI, 99mTc-sestamibi, has a long history of safe use. Biopsy capability has become available in recent years, with early clinical experience demonstrating technically successful biopsies of MBI-detected lesions. MBI has been shown to be an effective supplemental screening tool in women with dense breasts and is also utilized for breast cancer staging, assessment of response to neoadjuvant chemotherapy, problem solving, and as an alternative to breast MRI in women who have a contraindication to MRI. The degree of background parenchymal uptake on MBI shows promise as a tool for breast cancer risk stratification. Radiologist interpretation is guided by a validated MBI lexicon that mirrors the BI-RADS lexicon. With short interpretation times, a fast learning curve for radiologists, and a substantially lower cost than breast MRI, MBI provides many benefits in the practices in which it is utilized. This review will discuss the current state of MBI technology, clinical applications of MBI, MBI interpretation, radiation dose associated with MBI, and the future of MBI.
摘要：
分子乳腺成像（MBI）是一种核医学技术，在过去的二十年中取得了长足的发展。技术进步已经允许将给药剂量减少到现在可以接受筛查的程度。MBI中使用的最常见的放射性示踪剂，99mTc-sestamibi,有着悠久的安全使用历史。活检能力已成为近年来可用，早期临床经验表明，对MBI检测到的病变进行了技术上成功的活检。MBI已被证明是一种有效的补充筛查工具，用于乳房致密的女性，也用于乳腺癌分期。评估对新辅助化疗的反应，解决问题,作为对有MRI禁忌症的女性的乳腺MRI的替代方法。MBI的背景实质摄取程度显示出有望作为乳腺癌风险分层的工具。放射科医师的解释由经过验证的MBI词典指导，该词典反映了BI-RADS词典。由于口译时间短，放射科医生的快速学习曲线，而且成本比乳腺MRI低很多,MBI在使用它的实践中提供了许多好处。这篇综述将讨论MBI技术的现状，MBI的临床应用，MBI解释,与MBI相关的辐射剂量，MBI的未来
